Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

[Genetic abnormalities in the pathogenesis of ovarian cancer].

Yoshino K, Ueda Y, Kimura T, Kobayashi E, Fujita M, Enomoto T.

Nihon Rinsho. 2012 Jun;70 Suppl 4:480-7. Japanese. No abstract available.

PMID:
23156294
2.

[Molecular genetic of ovarian cancer].

Yanaihara N, Okamoto A, Ochiai K, Tanaka T.

Nihon Rinsho. 2012 Jun;70 Suppl 4:475-9. Japanese. No abstract available.

PMID:
23156293
3.

Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.

Huang HN, Lin MC, Tseng LH, Chiang YC, Lin LI, Lin YF, Huang HY, Kuo KT.

Histopathology. 2015 Mar;66(4):517-28. doi: 10.1111/his.12543. Epub 2014 Dec 22.

PMID:
25195947
4.

Acta Oncologica and a new generation of scientists in oncology.

Glimelius B, Johansen C, Muren LP, Nilbert M.

Acta Oncol. 2014 Jul;53(7):849-51. doi: 10.3109/0284186X.2014.913102. No abstract available.

PMID:
24954366
5.

Ovarian cancer : making its own rules-again.

Kohn EC, Hurteau J.

Cancer. 2013 Feb 1;119(3):474-6. doi: 10.1002/cncr.27833. Epub 2012 Dec 11. Review. No abstract available.

6.
7.

Molecular characterization of endometrial cancer: a correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mismatch repair protein expression, and PTEN, PIK3CA, KRAS, and BRAF mutation analysis.

Peterson LM, Kipp BR, Halling KC, Kerr SE, Smith DI, Distad TJ, Clayton AC, Medeiros F.

Int J Gynecol Pathol. 2012 May;31(3):195-205. doi: 10.1097/PGP.0b013e318231fc51.

PMID:
22498935
8.

PIK3CA alterations in Middle Eastern ovarian cancers.

Abubaker J, Bavi P, Al-Haqawi W, Jehan Z, Munkarah A, Uddin S, Al-Kuraya KS.

Mol Cancer. 2009 Jul 28;8:51. doi: 10.1186/1476-4598-8-51.

9.

[Familial breast cancer, ovarian cancer].

Inoue M.

Nihon Rinsho. 2006 Jun 28;Suppl 2:366-70. Review. Japanese. No abstract available.

PMID:
16817423
10.

[Genetic diagnosis of the endometrial cancer].

Kimura T, Fujita M, Kobayashi E, Ueda Y, Yoshino K, Enomoto T.

Nihon Rinsho. 2012 Jun;70 Suppl 4:367-71. Japanese. No abstract available.

PMID:
23156272
11.

BRAF: a driver of the serrated pathway in colon cancer.

Rustgi AK.

Cancer Cell. 2013 Jul 8;24(1):1-2. doi: 10.1016/j.ccr.2013.06.008.

12.

Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer.

Bosse T, ter Haar NT, Seeber LM, v Diest PJ, Hes FJ, Vasen HF, Nout RA, Creutzberg CL, Morreau H, Smit VT.

Mod Pathol. 2013 Nov;26(11):1525-35. doi: 10.1038/modpathol.2013.96. Epub 2013 May 24.

13.

Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.

Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM.

Am J Obstet Gynecol. 2008 Apr;198(4):351-6. doi: 10.1016/j.ajog.2008.01.005. Review.

14.

Unmasking the role of KRAS and BRAF pathways in MSI colorectal tumors.

Seruca R, Velho S, Oliveira C, Leite M, Matos P, Jordan P.

Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):5-9. doi: 10.1586/17474124.3.1.5. No abstract available.

PMID:
19210107
15.

Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.

Richards JS, Fan HY, Liu Z, Tsoi M, Laguë MN, Boyer A, Boerboom D.

Oncogene. 2012 Mar 22;31(12):1504-20. doi: 10.1038/onc.2011.341. Epub 2011 Aug 22.

16.

Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B.

Asaka S, Arai Y, Nishimura Y, Yamaguchi K, Ishikubo T, Yatsuoka T, Tanaka Y, Akagi K.

Carcinogenesis. 2009 Mar;30(3):494-9. doi: 10.1093/carcin/bgp017. Epub 2009 Jan 15.

PMID:
19147861
17.

[Examination of molecular markers used n the treatment of colon cancer].

Domagała P, Kowalik A.

Pol J Pathol. 2014 Dec;65(4 Suppl 1):S59-77. Review. Polish. No abstract available.

PMID:
26165036
18.

Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.

Carneiro JG, Couto PG, Bastos-Rodrigues L, Bicalho MA, Vidigal PV, Vilhena A, Amaral NF, Bale AE, Friedman E, De Marco L.

Genet Res (Camb). 2014;96:e002. doi: 10.1017/S0016672314000032. Epub 2014 Mar 5.

PMID:
24594201
19.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
20.

Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics.

Vergara D, Tinelli A, Martignago R, Malvasi A, Chiuri VE, Leo G.

Curr Cancer Drug Targets. 2010 Feb;10(1):107-16. Review.

PMID:
20088785

Supplemental Content

Support Center